Literature DB >> 25652151

Biosimilar versus generic drugs: same but different?

Katelijne van de Vooren1, Alessandro Curto, Livio Garattini.   

Abstract

Mesh:

Substances:

Year:  2015        PMID: 25652151     DOI: 10.1007/s40258-015-0154-9

Source DB:  PubMed          Journal:  Appl Health Econ Health Policy        ISSN: 1175-5652            Impact factor:   2.561


× No keyword cloud information.
  6 in total

1.  Competition in pharmaceuticals: more product- than price-oriented?

Authors:  Livio Garattini; Anna Padula
Journal:  Eur J Health Econ       Date:  2018-01

Review 2.  Introduction of biosimilar insulins in Europe.

Authors:  M Davies; D Dahl; T Heise; J Kiljanski; C Mathieu
Journal:  Diabet Med       Date:  2017-07-16       Impact factor: 4.359

Review 3.  Similar biologics in India: A story of access or potential for compromise?

Authors:  Ramesh Jois; Sukumar Mukherjee; S Rajeswari; P D Rath; Vishal Goyal; Disha Gupta
Journal:  Indian J Med Res       Date:  2020-11       Impact factor: 2.375

4.  Biosimilars: How Can Payers Get Long-Term Savings?

Authors:  Jorge Mestre-Ferrandiz; Adrian Towse; Mikel Berdud
Journal:  Pharmacoeconomics       Date:  2016-06       Impact factor: 4.981

5.  Prescribing generics: All in a name.

Authors:  Vandana Roy; Proteesh Rana
Journal:  Indian J Med Res       Date:  2018-05       Impact factor: 2.375

Review 6.  The biosimilar pathway in the USA: An analysis of the innovator company and biosimilar company perspectives and beyond.

Authors:  Lin-Chau Chang
Journal:  J Food Drug Anal       Date:  2019-04-30       Impact factor: 6.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.